Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jørgen A.L. Kurtzhals"'
Autor:
Appiah-Korang Labi, Karen L. Nielsen, Rasmus L. Marvig, Stephanie Bjerrum, Christabel Enweronu-Laryea, Marc Bennedbæk, Mercy J. Newman, Prosper K. Ayibor, Leif P. Andersen, Jørgen A.L. Kurtzhals
Publikováno v:
Emerging Infectious Diseases, Vol 26, Iss 9, Pp 2235-2238 (2020)
We sequenced 29 carbapenemase-producing Klebsiella pneumoniae isolates from a neonatal intensive care unit in Ghana. Twenty-eight isolates were sequence type 17 with blaOXA-181 and differed by 0–32 single-nucleotide polymorphisms. Improved surveill
Externí odkaz:
https://doaj.org/article/700f243fa65a4faca948fa7012918b29
Autor:
Amina Nardo-Marino, Andreas Glenthøj, John N. Brewin, Jesper Petersen, Thomas H. Braunstein, Jørgen A.L. Kurtzhals, Thomas N. Williams, David C. Rees
Publikováno v:
Blood. 140:1639-1640
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e2004cec8a2512330f5817fc8579706
https://doi.org/10.1182/blood-2022-165460
https://doi.org/10.1182/blood-2022-165460
Publikováno v:
Toxicology Letters. 167:162-164
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::707d1a8ad1472d2052b72fb2305c14fe
https://doi.org/10.1016/j.toxlet.2006.09.001
https://doi.org/10.1016/j.toxlet.2006.09.001
Autor:
George O. Adjei, MD, PhD, Seth K. Amponsah, PhD, Bamenla Q. Goka, MB. ChB, MRCP, FWACP, Christabel Enweronu-Laryea, MBBS, MSc, FRCPCH, Lorna Renner, MB. ChB, MPH, FRCPCH, FGCPS, Abdul Malik Sulley, MSc, Michael Alifrangis, MSc, PhD, Jorgen A.L. Kurtzhals, MD, PhD
Publikováno v:
Current Therapeutic Research, Vol 90, Iss , Pp 9-15 (2019)
Background: There is limited information on the safety or efficacy of currently recommended antimalarial drugs in patients with sickle cell disease (SCD), a population predisposed to worse outcomes if affected by acute malaria. Artesunate-amodiaquine
Externí odkaz:
https://doaj.org/article/661c4b34123b4770b6749e691cf1e354
Autor:
Seth K. Amponsah, PhD, George O. Adjei, MD, PhD, Christabel Enweronu-Laryea, MRCPCH, Kwasi A. Bugyei, PhD, Kosta Hadji-Popovski, MSc Pharm, Jorgen A.L. Kurtzhals, MD, PhD, Kim Kristensen, PhD
Publikováno v:
Current Therapeutic Research, Vol 84, Iss C, Pp e1-e6 (2017)
Background: Amikacin exhibits marked pharmacokinetic (PK) variability and is commonly used in combination with other drugs in the treatment of neonatal sepsis. There is a paucity of amikacin PK information in neonates from low-resource settings. Obje
Externí odkaz:
https://doaj.org/article/977daec50b79459487e304a04ae6cbbc